Start here if you're new
what it is
BeOne sells cancer medicines and is trying to turn one fast-growing drug into a much bigger global oncology business.
how it gets paid
Last year Beone Medicines made $5.3B in revenue.
why it's growing
Revenue grew 40.2% last year. U.s. sales totaled $739 million, representing 47% growth over the prior-year period, driven by robust demand across all indications and modest pricing improvement.
what just happened
Sales exploded, but the market stared at the 79.7% earnings miss instead.
At a glance
B++ balance sheet — above average — nothing keeping you up at night
30/100 earnings predictability — expect surprises
21.5% return on capital — every dollar works hard here
xvary composite: 58/100 — below average
$9B fy2029 rev est
What they do
BeOne sells cancer medicines and is trying to turn one fast-growing drug into a much bigger global oncology business.
BeOne wins because Brukinsa is already approved in 75 markets, with reimbursement in 57. Drug reimbursement → insurers and health systems paying for treatment → that is what turns approvals into real sales. If your drug replaces chemotherapy and patients stay on it long term, revenue can pile up without needing a brand-new launch every quarter.
How they make money
$5.3B
annual revenue · their business grew +40.2% last year
total revenue
$5.3B
+40.2%
The products that matter
BTK inhibitor for blood cancers
Brukinsa
$900M+ in one quarter
it already generates over $900M in a single quarter. that's not pipeline hope — that's a real franchise carrying the current story.
lead asset
commercial oncology drug portfolio
Oncology Portfolio
$5.3B · +39.0%
this portfolio generated $5.3B last year and grew 39.0%. that's the revenue base the market is valuing at roughly $40B.
core engine
late-stage clinical pipeline
Phase III and proof-of-concept programs
20+ Phase III trials
over 20 Phase III trials and more than 10 proof-of-concept readouts mean you are not paying only for today's drugs. you're also paying for how many of those shots actually land.
valuation swing factor
Key numbers
$0.19
fy eps est
That works out to about $0.19 per diluted share from filings.
$9B
fy2029 rev est
1821.4x
trailing p/e
You're paying about 1821.4x the last full year's earnings.
86.3%
gross margin
Gross profit kept about 86.3% of each revenue dollar.
Financial health
B++
strength
- balance sheet grade B++ — above average financial health
- risk rank 3 — safer than 50% of stocks
- price stability 15 / 100
- long-term debt $140M (0% of capital)
- net profit margin 23.0% — keeps 23 cents of every dollar in revenue
- return on equity 22% — $0.22 profit for every $1 investors have put in
B++ — functional but not a standout on the balance sheet.
Total return vs. market
You invested $10,000 in ONC 3 years ago → it's now worth $14,120.
The index would have given you $13,880.
source: institutional data · total return
What just happened
missed estimates
Sales exploded, but the market stared at the 79.7% earnings miss instead.
Latest quarterly revenue reached $3.8B, up 172% vs. prior year. But the Wall Street-tracked profit figure came in at $0.58 versus a $2.86 estimate, which drowned out the sales surge.
$3.8B
revenue
$0.58
eps
86.3%
gross margin
the number that mattered
The key number was the 79.7% miss versus the tracked profit estimate, because investors forgive biotech losses faster than they forgive confusion.
-
we are welcoming beone medicines ag into the institutional data.formerly known as beigene, ltd., beone medicines is a global oncology company engaged in the discovery and development of treatments that are affordable and accessible to cancer patients worldwide. the company has built a differentiated, wholly-owned franchise within hematology that includes a best-in-class btk (bruton tyrosine kinase) inhibitor, brukinsa (zanubrutinib). the drug inhibits the btk protein, a vital component of the b-cell receptor signaling pathway that allows cancer cells to survive and proliferate.
-
btk inhibitors are often taken long term, replacing chemotherapy in treating many blood cancers.
-
beone is solidly profitable.through the first nine months of 2025, the company had registered $6.14 in adjusted earnings per ads, largely on the strength of massive, high-margin sales of brukinsa, which generated over $900 million in revenue in the september quarter alone.
-
brukinsa is approved in 75 markets globally, with reimbursement in 57 of them.
-
u.s. sales totaled $739 million, representing 47% growth over the prior-year period, driven by robust demand across all indications and modest pricing improvement.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk is Brukinsa-led growth decelerating faster than the market expects.
high
Growth deceleration
2026 guidance of $6.2–$6.4B implies about 17–21% growth after 39.0% in 2025. That's still healthy. It's also a sharp slowdown in the number investors just got used to.
A slower top line can compress the premium multiple even if the business remains profitable
med
Pipeline execution risk
More than 20 Phase III trials and over 10 proof-of-concept readouts create upside. They also create many opportunities for disappointment.
Setbacks would hit sentiment first, then raise questions about how much of the $40B valuation belongs to future assets
med
Hematology concentration
Brukinsa generated over $900M in a single quarter. Great numbers. Also a reminder that one franchise is doing a lot of the work.
If prescription momentum softens, the whole growth narrative feels it quickly
med
BTK competition and pricing pressure
The BTK inhibitor market is crowded by larger pharmaceutical companies. When a category gets crowded, pricing gets less friendly.
Pressure on price or share could narrow margins from today's profitable level
A lot of the thesis comes down to one math problem: can a $5.3B oncology business keep growing fast enough to justify a ~$40B valuation while its lead franchise faces harder comps and real competition.
source: institutional data · regulatory filings · risk analysis
Pay attention to
the number
quarterly revenue versus the $6.2–$6.4B guide
If quarterly results start drifting below the 2026 path, the market will stop treating this as a premium-growth oncology story.
calendar
20+ Phase III trials and 10+ readouts
Biotech stocks can re-rate on data faster than on revenue. This calendar matters because a lot of future value sits there.
franchise trend
Brukinsa quarterly sales
Over $900M in one quarter is the anchor. You want to see that number keep climbing, not merely hold steady.
risk check
margin durability as competition builds
Beone already posts a 21.3% net margin. If competition bites into pricing, you'll see it in profitability before management says it out loud.
Analyst rankings
short-term outlook
average
momentum score 3 — in human-speak, analysts see a stock acting mostly like the market, not a clear short-term outlier.
risk profile
average
stability score 3 means typical stock risk. Not a bunker. Not chaos.
chart momentum
top 20%
technical score 2 suggests above-average price performance expectations over the next year. The chart has been helping.
earnings predictability
30 / 100
Low predictability means future quarters can move around more than mature large-cap pharma names. Expect volatility around results.
source: institutional data
Institutional activity
institutions have been net buying for 2 consecutive quarters — 148 buyers vs. 113 sellers in 3q2025. total institutional holdings: 33.4M shares. net buying for 2 quarters.
source: institutional data
Price targets
3-5 year target range
$230
$553
$346
current price
$392
target midpoint · +13% from current · 3-5yr high: $530 (+55% · 13% ann'l return)
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive